The global Avagacestat market was valued at US$ million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.   Avagacestat is an oral gamma secretase inhibitor designed for selective inhibition of amyloid beta synthesis. Download FREE Sample of...